Enarodustat

Enarodustat
Clinical data
Trade names	Enaroy
Other names	JTZ-951
Legal status
Legal status	Rx-only (Japan);
Identifiers
	IUPAC name 2-{[7-Hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]formamido}acetic acid;
CAS Number	1262132-81-9 ;
PubChem CID	50899324 ;
DrugBank	14985 ;
ChemSpider	64835234 ;
UNII	JSK7TUA223 ;
KEGG	D11523 ;
ChEMBL	ChEMBL4297619 ;
Chemical and physical data
Formula	C17H16N4O4
Molar mass	340.339 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O;
	InChI InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24); Key:FJYRBJKWDXVHHO-UHFFFAOYSA-N;

Last updated December 31, 2025

Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (CKD). Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH).^[1]

The drug was approved in September 2020 in Japan for anemia associated with CKD^[2] and is currently in clinical development in the United States and South Korea.^[3] The drug is being developed by Japan Tobacco and JW Pharmaceutical.^[4]

References

↑ Hirota K (April 2021). "HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review". Biomedicines. 9 (5): 468. doi: 10.3390/biomedicines9050468 . PMC 8146675 . PMID 33923349.
↑ "JT Receives Manufacturing and Marketing Approval of ENAROY Tablets 2mg･4mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan" (PDF) (Press release). September 25, 2020.
↑ Markham A (January 2021). "Enarodustat: First Approval". Drugs. 81 (1): 169–174. doi:10.1007/s40265-020-01444-3. PMID 33320297. S2CID 229163684.
↑ "Enarodustat - Japan Tobacco". Adis Insight.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Hirota K (April 2021). "HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review". Biomedicines. 9 (5): 468. doi: 10.3390/biomedicines9050468 . PMC 8146675 . PMID 33923349.

[2] "JT Receives Manufacturing and Marketing Approval of ENAROY Tablets 2mg･4mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan" (PDF) (Press release). September 25, 2020.

[3] Markham A (January 2021). "Enarodustat: First Approval". Drugs. 81 (1): 169–174. doi:10.1007/s40265-020-01444-3. PMID 33320297. S2CID 229163684.

[4] "Enarodustat - Japan Tobacco". Adis Insight.

[1]

[2]

[3]

[4]